packageAgalsidaseAlfa

agalsidase alfa

Extends from Pharmacolibrary.Interfaces.PartialSubstance (Identity and physicochemical constants of one drug (Drugs.Substances)).

Information

Agalsidase alfa is an enzyme replacement therapy used to treat Fabry disease. It is authorised in the European Union and is an approved medicine.

Summary written by glm-5.3-flash from Wikidata Q288705 and the WHO ATC classification and the EMA medicines list; not checked by a person.

name:agalsidase alfa
ATC codes:A16AB03
DrugBank:DB15874
Wikidata:Q288705
molar mass:959.2 g/mol (Drugs.Common 25.09, not verified)

Parameters

TypeNameDefaultDescription
Stringname (from PartialSubstance)""INN / common name
String[:]atcCodes (from PartialSubstance)fill("", 0)all WHO ATC codes of the drug
StringdrugbankId (from PartialSubstance)""e.g. DB00758
StringpubchemCid (from PartialSubstance)""PubChem compound id
StringchebiId (from PartialSubstance)""ChEBI id (number)
StringwikidataId (from PartialSubstance)""e.g. Q410238
Stringformula (from PartialSubstance)""molecular formula
Modelica.Units.SI.MolarMassM (from PartialSubstance)0molar mass; 0 = unknown
ReallogP (from PartialSubstance)Modelica.Constants.infoctanol-water partition coefficient (log10); inf = unknown